PMID- 38504360
OWN - NLM
STAT- MEDLINE
DCOM- 20240321
LR  - 20240323
IS  - 1546-0096 (Electronic)
IS  - 1546-0096 (Linking)
VI  - 22
IP  - 1
DP  - 2024 Mar 19
TI  - Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the 
      first Chinese experience.
PG  - 38
LID - 10.1186/s12969-024-00974-4 [doi]
LID - 38
AB  - BACKGROUND: Systemic juvenile idiopathic arthritis (sJIA) is a severe form of 
      juvenile arthritis that is characterized by chronic joint inflammation and 
      systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor 
      monoclonal antibody tocilizumab is an effective treatment. However, some patients 
      still experience persisting or recurrent symptoms and the real-world 
      effectiveness of canakinumab in Chinese patients with sJIA has never been 
      reported. Therefore, this study aimed to assess the efficacy and safety of 
      canakinumab in Chinese patients with sJIA using real-world data. METHODS: We 
      conducted a retrospective study on children with active sJIA. Clinical features, 
      laboratory data, corticosteroid dosage, and adverse events (AEs) were collected 
      at baseline and at 4, 8, 12, and 24 weeks after initiating canakinumab treatment. 
      RESULTS: Seven female and four male patients were included in the study. All 
      patients had previously been treated with tocilizumab and were administered 
      canakinumab for 12.4 +/- 3.4 months. Notably, significant improvements were 
      observed in both clinical signs and symptoms as well as laboratory indicators. 
      Four children under corticosteroid treatment were able to successfully 
      discontinue their corticosteroid therapy: one at week 4, two at week 12, and one 
      at week 24. Notably, there was a significant reduction in the number of tender 
      and swollen joints (P = 0.0059) as well as the systemic juvenile arthritis 
      disease activity score (P < 0.0001). The most common AE was infection, but no 
      patients experienced serious AEs. No cases of macrophage activation syndrome or 
      death were reported during the follow-up period. CONCLUSIONS: Canakinumab was 
      found to be potentially efficacious and safe in Chinese patients with sJIA. No 
      new AEs were observed with canakinumab treatment.
CI  - (c) 2024. The Author(s).
FAU - Qiu, Lingzhi
AU  - Qiu L
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
FAU - Ma, Le
AU  - Ma L
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
FAU - Xie, Yifan
AU  - Xie Y
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
FAU - Jin, Jing
AU  - Jin J
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
FAU - Pan, Yuting
AU  - Pan Y
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
FAU - Li, Shumin
AU  - Li S
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China.
FAU - Fan, Zhidan
AU  - Fan Z
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China. 
      zhidanfan@njmu.edu.cn.
FAU - Yu, Haiguo
AU  - Yu H
AUID- ORCID: 0000-0001-8255-9390
AD  - Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical 
      University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China. 
      haiguo_yu@njmu.edu.cn.
LA  - eng
GR  - 2021YFC2702000/National Key R&D Program of China/
GR  - 82271838/National Natural Science Foundation of China/
GR  - 81800438/National Natural Science Foundation of China/
GR  - 82300774/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20240319
PL  - England
TA  - Pediatr Rheumatol Online J
JT  - Pediatric rheumatology online journal
JID - 101248897
RN  - 37CQ2C7X93 (canakinumab)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Child
MH  - Humans
MH  - Male
MH  - Female
MH  - *Arthritis, Juvenile/drug therapy
MH  - Antibodies, Monoclonal/adverse effects
MH  - Retrospective Studies
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - *Antibodies, Monoclonal, Humanized
PMC - PMC10949691
OTO - NOTNLM
OT  - Canakinumab
OT  - Interleukin-1
OT  - Systemic juvenile idiopathic arthritis
COIS- The authors declare that they have no competing interests.
EDAT- 2024/03/20 06:45
MHDA- 2024/03/21 12:47
PMCR- 2024/03/19
CRDT- 2024/03/20 00:55
PHST- 2024/01/06 00:00 [received]
PHST- 2024/03/10 00:00 [accepted]
PHST- 2024/03/21 12:47 [medline]
PHST- 2024/03/20 06:45 [pubmed]
PHST- 2024/03/20 00:55 [entrez]
PHST- 2024/03/19 00:00 [pmc-release]
AID - 10.1186/s12969-024-00974-4 [pii]
AID - 974 [pii]
AID - 10.1186/s12969-024-00974-4 [doi]
PST - epublish
SO  - Pediatr Rheumatol Online J. 2024 Mar 19;22(1):38. doi: 
      10.1186/s12969-024-00974-4.